Search Result

Results for "

blood glucose

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (1) SGLT (8) 11β-HSD (1) Adrenergic Receptor (2) Akt (2) Aldose Reductase (1) AMPK (6) Amylases (1) Antibiotic (1) Apoptosis (5) Autophagy (3) Bacterial (5) Biochemical Assay Reagents (4) c-Myc (2) Cannabinoid Receptor (1) Cytochrome P450 (1) Dipeptidyl Peptidase (3) Endogenous Metabolite (7) ERK (1) Estrogen Receptor/ERR (1) FABP (1) FBPase (1) Ferroptosis (3) Fluorescent Dye (1) Free Fatty Acid Receptor (2) GCGR (9) GLP Receptor (4) Glucocorticoid Receptor (1) Glucokinase (3) Glucosidase (17) GPR119 (3) Histone Acetyltransferase (1) Insulin Receptor (2) Isotope-Labeled Compounds (2) JAK (2) Keap1-Nrf2 (2) Melatonin Receptor (1) Mineralocorticoid Receptor (1) MMP (2) NF-κB (4) Nuclear Hormone Receptor 4A/NR4A (1) PDK-1 (1) PEPCK (1) Phosphatase (4) PI3K (5) Potassium Channel (2) PPAR (14) PROTACs (1) Reactive Oxygen Species (2) STAT (2)
By Research Areas:	Cancer (18) Cardiovascular Disease (3) Endocrinology (6) Infection (3) Inflammation/Immunology (9) Metabolic Disease (112) Neurological Disease (9)
Oligonucleotides:	Polymers (1) Antisense Oligonucleotides (2)

128

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active *sodium glucose* cotransporter (SGLT2)** inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Others	Inflammation/Immunology
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active *sodium-glucose* cotransporter (SGLT) 2** inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .

HY-N12353

Stevisalioside A	Phosphatase	Metabolic Disease
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-121565

SaRI 59-801	Others	Metabolic Disease Endocrinology
SaRI 59-801 is an orally effective hypoglycemic compound. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-148575

α-Glucosidase-IN-23	Glucosidase	Metabolic Disease
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC₅₀ value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes .

HY-136631

PF-04279405	Glucokinase	Metabolic Disease
PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC₅₀=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P5578

A8SGLP-1	GCGR	Metabolic Disease
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .

HY-P5578A

A8SGLP-1 TFA	GCGR	Metabolic Disease
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .

HY-143226

DK1	Estrogen Receptor/ERR	Metabolic Disease
DK1 is a potent modulator of estrogen related receptor. DK1 has an ability in reducing blood glucose, and impacts the activity of ERRα receptor. DK1 has the potential for the research of diabetes .

HY-150560

α-Glucosidase-IN-11	Glucosidase	Metabolic Disease
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC₅₀ value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels .

HY-103433

K579	Dipeptidyl Peptidase	Metabolic Disease
K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .

HY-14860

1-Deoxynojirimycin 3 Publications Verification Duvoglustat	Glucosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-14860A

1-Deoxynojirimycin hydrochloride 3 Publications Verification Duvoglustat hydrochloride	Glucosidase PI3K Bacterial Antibiotic	Infection Metabolic Disease
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-148189

Aldometanib 4 Publications Verification LXY-05-029	AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

HY-151138

α-Glucosidase-IN-16	Glucosidase	Metabolic Disease
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .

HY-123171

ASP8497	Others	Metabolic Disease
ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .

HY-14860R

1-Deoxynojirimycin (Standard)	Glucosidase PI3K	Metabolic Disease
1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-15344

Ketone monoester 2 Publications Verification	Others	Neurological Disease Metabolic Disease
Ketone monoester is an orally available ketone monoester that serves as a source of nutritional ketones. Ketone monoester increases plasma beta-hydroxybutyrate, acetoacetate, blood glucose, blood sodium, and blood creatinine levels in mouse models. Ketone monoester has the potential to improve athletic performance and endurance in animals. Ketone monoester partially prevents myasthenia in septic mice. Ketone monoester may also be used to study Parkinson's disease or diabetes .

HY-163996

DD202-114	GLP Receptor	Metabolic Disease
DD202-114 is a potent and selective GLP1R agonist. DD202-114 promots cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential for the research of type 2 diabetes (T2DM) and obesity .

HY-W005629

Leelamine	Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

HY-117446

AS-1669058	GPR119	Metabolic Disease
AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-B0920

Tolazamide U-17835	Others	Endocrinology
Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes.

HY-117446A

AS-1669058 free base	GPR119	Metabolic Disease
AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.

HY-107863

Fructooligosaccharides Oligolevulose	Biochemical Assay Reagents	Metabolic Disease
Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .

HY-157370

Blood Enrichment Medium	Biochemical Assay Reagents	Others
Blood Enrichment Medium can be used for enrichment culture of pathogenic bacteria in blood. Blood Enrichment Medium ingredients include peptone, beef extract powder, NaCl, glucose, sodium citrate, para-aminobenzoic acid, magnesium sulfate, phenol red .

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester	Others	Metabolic Disease
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-W010031

1-Methyluric acid	Endogenous Metabolite	Metabolic Disease
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-101637

Reglitazar JT 501	PPAR	Metabolic Disease
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .

HY-N2421

Sequoyitol 1 Publications Verification 5-O-Methyl-myo-inositol	Others	Metabolic Disease
Sequoyitol (5-O-Methyl-myo-inositol) is isolated from plants. Sequoyitol (5-O-Methyl-myo-inositol) decreases blood glucose, improves glucose intolerance, and is used to treat diabetes .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-117978

LY2922083	Free Fatty Acid Receptor	Endocrinology
LY2922083 and related compounds LY2881835 and LY2922470 are spiperidine and tetrahydroquinolinic acid derivatives that are potent GPR40 agonists. LY2922083 activates GPR40 in response to elevated blood glucose and has the potential to be a glucose-lowering agent .

HY-128923

SKF-34288 hydrochloride 4 Publications Verification 3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride	PEPCK	Metabolic Disease
SKF-34288 (3-Mercaptopicolinic acid) hydrochloride is an orally active phosphoenolpyruvate carboxykinase (PEPCK) inhibitor (K_i: 2-9 μM). SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits Asn metabolism and increases amino acids and amides .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral *sodium-glucose* cotransporter 2 (SGLT2*) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose* reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-N13082

Deacetylescin Ia	Others	Metabolic Disease
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

HY-161281

α-Glucosidase-IN-49	Glucosidase	Metabolic Disease
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC₅₀ of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .

HY-150012

N-Lactoyl-Phenylalanine 1 Publications Verification Lac-Phe	Endogenous Metabolite	Metabolic Disease Endocrinology
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-159696A

ISIS 449884 sodium	GCGR	Metabolic Disease
ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159696

ISIS 449884	GCGR	Metabolic Disease
ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-162893

SX29	Glucosidase	Metabolic Disease
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC₅₀ value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .

HY-12614

AMG-1694	Glucokinase	Metabolic Disease
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC₅₀ of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .

HY-148529

Midaglizole (±)-DG5128 free base; DG5128 free base	Adrenergic Receptor	Metabolic Disease
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .

HY-116930

S-20928	Melatonin Receptor	Metabolic Disease
S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .

HY-117459

E-3030 free acid	Others	Metabolic Disease
E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.

HY-12219B

MSI-1701	Others	Metabolic Disease
MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.

HY-N3960

Glycyrin	PPAR Bacterial	Infection Metabolic Disease
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

Cat. No.	Product Name

HY-L045

Oxygen Sensing Compound Library

2,656 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 2,656 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Type

HY-107863

Fructooligosaccharides Oligolevulose	Carbohydrates
Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .

HY-112624C

Dextran (MW 40000)

Thickeners

Dextran (MW 40000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.

HY-112624B

Dextran T70 (MW 70,000)

Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)

Drug Delivery Thickeners

Dextran T70 (MW 70,000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.

HY-157370

Blood Enrichment Medium	Microbial Culture
Blood Enrichment Medium can be used for enrichment culture of pathogenic bacteria in blood. Blood Enrichment Medium ingredients include peptone, beef extract powder, NaCl, glucose, sodium citrate, para-aminobenzoic acid, magnesium sulfate, phenol red .

Cat. No.	Product Name	Target	Research Area

HY-137874

L-Glutamic γ-monohydroxamate	Peptides	Metabolic Disease Cancer
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo .

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P5578

A8SGLP-1	GCGR	Metabolic Disease
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .

HY-P5578A

A8SGLP-1 TFA	GCGR	Metabolic Disease
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Gramineae Coix lacryma-jobi Linn. Plants Disease Research Fields	Others
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-14860

1-Deoxynojirimycin 3 Publications Verification Duvoglustat	Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Source classification Metabolic Disease Plants Moraceae Disease Research Fields Morus alba Linn.	Glucosidase PI3K
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-14860A

1-Deoxynojirimycin hydrochloride 3 Publications Verification Duvoglustat hydrochloride	Structural Classification Commelinaceae Classification of Application Fields Source classification Metabolic Disease Commelina communis Plants Disease Research Fields Saccharides Monosaccharides	Glucosidase PI3K Bacterial Antibiotic
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester	Structural Classification Iridoids Classification of Application Fields Terpenoids Source classification Rubiaceae Metabolic Disease Plants Disease Research Fields Hedyotis diffusa Willd.	Others
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-W010031

1-Methyluric acid	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Other disease Source classification Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-N2421

Sequoyitol 1 Publications Verification 5-O-Methyl-myo-inositol	Natural Products Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Metabolic Disease Plants Disease Research Fields	Others
Sequoyitol (5-O-Methyl-myo-inositol) is isolated from plants. Sequoyitol (5-O-Methyl-myo-inositol) decreases blood glucose, improves glucose intolerance, and is used to treat diabetes .

HY-150012

N-Lactoyl-Phenylalanine 1 Publications Verification Lac-Phe	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
N-Lactoyl-Phenylalanine is a blood-derived signaling metabolite that can be induced by exercise. N-Lactoyl-Phenylalanine can reduce obesity and improve glucose tolerance .

HY-N12353

Stevisalioside A	Structural Classification Isodon hispidus (Bentham) Murata Polysaccharides Source classification Plants Compositae Saccharides	Phosphatase
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-14860R

1-Deoxynojirimycin (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Source classification Plants Moraceae Morus alba Linn.	Glucosidase PI3K
1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .

HY-N13082

Deacetylescin Ia	Aesculus chinensis Bunge Triterpenes Structural Classification Terpenoids Hippocastanaceae Source classification Plants	Others
Deacetylescin Ia (compound 12) is a deacetylated compound with anti-hyperglycemic effects that can be extracted from the debittered Aesculus and deacetylated at the C-22 position. Deacetylescin Ia (100 mg/kg) can inhibit blood glucose elevation in mouse glucose tolerance tests .

HY-N3960

Glycyrin	Structural Classification Leguminosae Source classification Coumarins Phenylpropanoids Plants Glycyrrhiza uralensis Fisch.	PPAR Bacterial
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

HY-N1503R

Methyl deacetylasperulosidate (Standard)	Structural Classification Iridoids Terpenoids Source classification Rubiaceae Plants Hedyotis diffusa Willd.	Others
Methyl deacetylasperulosidate (Standard) is the analytical standard of Methyl deacetylasperulosidate. This product is intended for research and analytical applications. Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-N0807

Swertiamarin	Structural Classification Monophenols other families Classification of Application Fields Phenols Zanthoxylum chiloperone var. angustifolium Metabolic Disease Plants Disease Research Fields Cancer	MMP NF-κB JAK Keap1-Nrf2
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-N0807R

Swertiamarin (Standard)	Structural Classification Monophenols other families Phenols Zanthoxylum chiloperone var. angustifolium Plants	MMP NF-κB JAK Keap1-Nrf2
Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis .

HY-N4195

Resveratroloside 1 Publications Verification Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside	Cardiovascular Disease Structural Classification Stilbenes Classification of Application Fields Polygonaceae Source classification Reynoutria japonica Houtt. Phenols Polyphenols Plants Disease Research Fields	Glucosidase
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC₅₀ of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .

HY-N11551

Salvifaricin	Artemisia frigida Willd. Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants	Others
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-13956R

Pioglitazone (Standard)	Human Gut Microbiota Metabolites Source classification Endogenous metabolite	PPAR Ferroptosis
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N3015

Bruceine E	Structural Classification Simaroubaceae Classification of Application Fields Terpenoids Source classification Metabolic Disease Diterpenoids Plants Disease Research Fields Brucea javanica (L.) Merr.	Others
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .

HY-W050031

(S)-3-Hydroxybutanoic acid 2 Publications Verification (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.

HY-129297

CMPF	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-N0330

Momordin Ic 3 Publications Verification	Kochia scoparia L. Schrad. Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Chenopodiaceae Cancer	Apoptosis Autophagy PI3K c-Myc
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl₄ (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-N0330R

Momordin Ic (Standard)	Kochia scoparia L. Schrad. Triterpenes Structural Classification Terpenoids Source classification Plants Chenopodiaceae	Apoptosis Autophagy PI3K c-Myc
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-B2163

Astaxanthin Maximum Cited Publications 8 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Whitening Agent Research on Agricultural Breeding Food Research Agricultural Research Microorganisms Sunscreen Terpenoids Pigments Diterpenoids Cosmetic Research Disease Research Fields	PPAR Reactive Oxygen Species STAT NF-κB Apoptosis
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .

HY-N2181

Acetylshikonin 1 Publications Verification	Quinones Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Boraginaceae Inflammation/Immunology Disease Research Fields	Cytochrome P450 Apoptosis Bacterial Autophagy
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC₅₀=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .

HY-B2163R

Astaxanthin (Standard)	Structural Classification Microorganisms Terpenoids Source classification Diterpenoids	PPAR Reactive Oxygen Species STAT NF-κB Apoptosis
Astaxanthin (Standard) is the analytical standard of Astaxanthin. This product is intended for research and analytical applications. Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .

Cat. No.	Product Name	Chemical Structure

HY-W010031S1

1-Methyluric acid-d3
1-Methyluric acid-d3 is the deuterium labeled 1-Methyluric acid (HY-W010031). 1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels .

HY-B2099S

Buformin-d9 hydrochloride
Buformin-d₉ (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].

Cat. No.	Product Name		Classification